SELLAS Life Sciences Group Inc buy melinda
Start price
08.09.20
/
50%
€1.72
Target price
04.11.21
€2.00
Performance (%)
386.91%
End price
05.11.21
€8.37
Summary
This prediction ended on 05.11.21 with a price of €8.37. With a performance of 386.91% the BUY prediction by melinda was a big success. melinda has 50% into this predictionSELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
SELLAS Life Sciences Group Inc | 1.520% | 1.520% | -13.150% | -84.746% |
iShares Core DAX® | 1.937% | 1.473% | 18.596% | 15.757% |
iShares Nasdaq 100 | -1.186% | -0.040% | 27.123% | 35.363% |
iShares Nikkei 225® | 1.938% | 4.205% | 17.502% | 10.532% |
iShares S&P 500 | -0.023% | 0.109% | 24.843% | 36.692% |
Comments by melinda for this prediction
In the thread SELLAS Life Sciences Group Inc diskutieren
Buy mit Kursziel 2,0
In the thread Trading SELLAS Life Sciences Group Inc
Die von melinda gewählte maximale Laufzeit wurde überschritten
Stopped prediction by melinda for SELLAS Life Sciences Group Inc
SELLAS Life Sciences Group Inc
Start price
Target price
Perf. (%)
€101.93
09.11.18
09.11.18
€162.36
13.11.18
13.11.18
-9.73%
13.11.18
13.11.18
SELLAS Life Sciences Group Inc
Start price
Target price
Perf. (%)
€62.24
15.10.18
15.10.18
€135.30
07.11.18
07.11.18
22.75%
07.11.18
07.11.18
SELLAS Life Sciences Group Inc
Start price
Target price
Perf. (%)
€47.36
31.08.18
31.08.18
€90.20
01.10.18
01.10.18
12.38%
01.10.18
01.10.18
SELLAS Life Sciences Group Inc
Start price
Target price
Perf. (%)
€9,389.8
30.06.16
30.06.16
€27,060
19.07.16
19.07.16
16.22%
19.07.16
19.07.16